Maia Hugo, Haddad Clarice, Coelho Genevieve, Casoy Julio
Centro de Pesquisas e Assistência em Reprodução Humana (CEPARH) & Instituto da Mulher, Rua Caetano Moura, 35, 40210-341 Salvador, Bahia, Brazil.
Womens Health (Lond). 2012 Nov;8(6):647-58. doi: 10.2217/whe.12.52.
Epigenetic changes favoring the transcription of the aromatase gene in the endometrium allow endometrial cells to survive in ectopic locations by producing estrogens that spare them from destruction through activated macrophages. Local estrogen production hastens prostaglandin synthesis by stimulating COX-2 activity, thus creating a self-perpetuating sequence of augmented estrogen formation and enhanced inflammation. Repetitive retrograde menstruation reintroduces aromatase-positive endometrial cells endowed with the capacity to implant and invade the peritoneum. In order to control endometriosis, an effective medication must inhibit aromatase, block COX-2, decrease fibrosis and induce amenorrhea. Within this framework, progestins, either alone or in the form of oral contraceptives, appear as first-line treatment for endometriosis owing to their capacity to block enzymes such as aromatase and COX-2.
子宫内膜中有利于芳香化酶基因转录的表观遗传变化,使子宫内膜细胞能够通过产生雌激素在异位部位存活,这些雌激素可使它们免受活化巨噬细胞的破坏。局部雌激素的产生通过刺激COX-2活性加速前列腺素的合成,从而形成雌激素生成增加和炎症增强的自我延续序列。反复的逆行月经会再次引入具有植入和侵袭腹膜能力的芳香化酶阳性子宫内膜细胞。为了控制子宫内膜异位症,一种有效的药物必须抑制芳香化酶、阻断COX-2、减少纤维化并诱导闭经。在此框架内,孕激素单独使用或以口服避孕药的形式出现,由于它们能够阻断芳香化酶和COX-2等酶,因此成为子宫内膜异位症的一线治疗方法。